Suicide Risk Recognition and Prevention
Clinical Snapshot
Suicide is a leading, and largely preventable, cause of death in Canada. Recent Public Health Agency of Canada surveillance data place the national toll at approximately 4,750 deaths per year — a rate of roughly 11.8 per 100,000 population, essentially stable from 2020 through 2023, with preliminary 2024 data suggesting a modest decline.[1] The burden is not evenly distributed: the suicide rate among men is almost 3 times the rate among women, and men account for close to three-quarters of all suicide deaths despite comprising half the population; nationally, the highest rates are seen among men aged 45-64.[1] Every one of these deaths sits behind a much larger number of attempts, and a still larger number of people who experience suicidal thoughts without ever attempting — each representing a genuine opportunity for a caring, well-timed intervention.
This chapter is written specifically for the pharmacist's own scope of practice, not as a general mental-health primer. Two points anchor everything that follows. First, asking directly and compassionately about suicidal thoughts does not increase risk — this is a genuinely evidence-based reassurance, not simply reassuring-sounding advice, and a fear of "putting the idea in someone's head" should never be the reason a pharmacist stays silent after noticing a warning sign.[2] Second, means restriction — reducing a person's access to a lethal method during a period of acute risk, with safe medication storage and thoughtful dispensing practice as its most directly pharmacist-relevant form — is one of the few suicide-prevention interventions with genuine, population-level evidence of reducing deaths, and it sits squarely within a pharmacist's own professional scope every single day.[3][4] Pharmacists are also, in practical terms, uniquely positioned to help: among the most frequently and repeatedly accessed regulated health professionals, reachable without an appointment, and the professional who directly dispenses the very medications at the centre of this chapter's safe-storage counselling. Canada's national response — including the 9-8-8 Suicide Crisis Helpline, launched 30 November 2023 and staffed 24 hours a day by phone and text in English and French — gives every pharmacist a genuine, immediate resource to invoke in the moment, not only a referral to arrange later.[5][6]
Recognize the Condition
The suicidal-ideation spectrum
Suicide risk is not a single, on/off state — it exists along a spectrum of increasing severity, a framework reflected in validated tools such as the Columbia-Suicide Severity Rating Scale (see Assessment & Diagnosis).[7] In rising order of acuity: a passive wish to be dead or to not wake up, without any active thought of self-directed action; active thoughts of suicide without any specific plan; active thoughts with a plan but no expressed intent to act on it; active thoughts with both a plan and expressed intent; and active preparatory behaviour. Where a specific patient falls on this spectrum is exactly what determines whether an encounter proceeds to this chapter's emergency pathway or to a non-emergency, supportive one (see Red Flags & Refer and Choose Initial Treatment) — which is why a brief, structured follow-up conversation after any positive screen matters far more than the screen result alone.
Behavioural and verbal warning signs a pharmacist may notice
- Direct or indirect statements suggesting finality or hopelessness — "I can't keep doing this," "everyone would be better off without me," "there's no point anymore" — said in a tone or context that feels different from ordinary venting.
- Marked withdrawal, or a sudden, uncharacteristic reduction in engagement with usual care and usual conversation.
- Giving away prized possessions, or making comments that sound like final arrangements.
- A sudden sense of calm or relief following a period of visible, severe depression or distress — a widely recognized possible warning sign that a decision has been reached, not necessarily a sign that things have genuinely improved; this pattern specifically should prompt a direct check-in rather than relief on the clinician's part.
- Increased alcohol or substance use, visible agitation, or conversely a flat, uncharacteristic apathy.
- Expressions of feeling like a burden to others, or of having no reason to keep going.
- A family member or caregiver directly voicing concern about a patient's mood, behaviour, or safety at pickup — take this seriously as a genuine clinical signal, not a side conversation.
Medication-related behavioural patterns specific to a pharmacy encounter
A pharmacist sees patterns other clinicians typically do not, simply by virtue of the refill relationship. None of the following is diagnostic on its own, but each is worth a direct, private follow-up conversation:
- Repeated early refill requests without a clear clinical explanation.
- A request to fill an entire remaining course, or several refills, all at once, outside a patient's normal, established pattern.
- Sudden interest in personally "using up" a discontinued or no-longer-needed medication rather than returning it through the pharmacy's own take-back process.
- A marked, unexplained change in a long-standing patient's usual pickup routine, communication style, or appearance.
Acute crises are often time-limited — the clinical logic behind means restriction
A genuinely important, evidence-based point that should inform every conversation in this chapter: many suicidal crises are acute and pass within a period of hours to days, particularly once immediate access to a means is delayed and the person connects with support in the meantime.[4][3] This is precisely why means restriction works even when it does nothing on its own to treat the underlying condition driving the crisis — it buys the single most valuable thing during an acute crisis: time, for the crisis to pass and for care to be engaged (see Choose Initial Treatment and Drug Tables).
Risk Factors
- A prior suicide attempt — the single strongest predictor of a future attempt or completed suicide of any known factor, and one that should always be asked about directly rather than assumed from the chart alone.[8]
- Mental illness — major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder, and personality disorders (see the Borderline Personality Disorder chapter) all carry substantially elevated risk, especially when untreated, undertreated, or recently worsened.[8]
- Substance use disorder — independently elevates risk, increases impulsivity, and very frequently compounds other risk factors on this list rather than acting alone.
- Social isolation and low connectedness — living alone, a thin or recently disrupted social support network, or a recent loss of a key relationship.
- A recent major loss or acute life crisis — relationship breakdown, job or financial loss, legal trouble, a new or worsening serious medical diagnosis, chronic pain, or bereavement.
- Access to a lethal means during a period of acute risk — the specific factor this chapter's means-restriction centerpiece exists to address (see Choose Initial Treatment and Drug Tables).[3]
- Recent discharge from psychiatric hospitalization, or a recent emergency department visit for self-harm — a distinctly time-limited window of markedly elevated risk, not a fading concern once the acute admission is over (see Red Flags & Refer and Special Populations).[9]
- Demographic and population-specific patterns in Canada — men die by suicide at almost 3 times the rate of women despite women reporting more non-fatal attempts, with the highest national rates among men aged 45-64; some First Nations, Inuit, and Métis communities experience suicide rates substantially above the national average, reflecting the ongoing impact of colonization, intergenerational trauma, and inequitable access to culturally safe care; 2SLGBTQ+ individuals, particularly youth, face elevated risk tied to stigma, discrimination, and family rejection; older adults, especially older men, remain an under-recognized higher-risk group; and healthcare workers, first responders, and military personnel face occupational-context elevated risk.[1][6]
- A family history of suicide or a suicide attempt.
- A history of trauma, abuse, or other significant adverse experiences.
Red Flags & Refer
Active suicidal ideation together with a specific plan, expressed intent, and/or reported access to a means requires emergency-level action in the same encounter — never routine follow-up. This is the single most important escalation rule in this chapter.
- Call Canada's 9-8-8 Suicide Crisis Helpline together with the patient — by phone or text, available 24 hours a day in English and French — or call 911 or local emergency services immediately if there is any immediate danger.[5]
- Do not leave the person alone, even briefly, while help is arranged; if they are on the phone, keep them on the line; if a second staff member is available, have them stay with the patient while help is arranged.
- A first presentation of significant risk in a patient with no existing mental health care team also warrants urgent, same-day connection to care, even short of an immediate plan.
- Recent discharge from psychiatric hospitalization or an emergency department visit for self-harm within the past days to weeks — a distinctly elevated-risk window in its own right (see Special Populations).[9]
- New or worsening suicidal ideation in the postpartum period, or any concern for infant safety, warrants the same emergency escalation described here — see the Postpartum Depression chapter's Red Flags & Refer section for the related and equally emergent presentation of postpartum psychosis.
Never dismiss a disclosure as attention-seeking — every disclosure is a genuine clinical symptom warranting a compassionate, structured response, and asking a direct follow-up question does not increase risk.[2]
Assessment & Diagnosis
Ask directly — and know that asking does not increase risk
Use plain, direct, non-euphemistic language: "Are you having thoughts of suicide?" or "Are you thinking about killing yourself?" rather than a softened or indirect phrasing that a distressed patient can too easily deflect. A systematic review of the evidence found no study demonstrating that asking about suicide or related behaviour increases suicidal ideation or distress — if anything, several of the studies reviewed suggested that acknowledging and talking about it may reduce distress rather than increase it.[2] This is one of the most useful, genuinely evidence-based facts a pharmacist can carry into this conversation: a fear of "putting the idea in someone's head" should never be a reason to stay silent once a warning sign has been noticed (see Recognize the Condition).
Brief, validated screening tools usable in a pharmacy encounter
Ask Suicide-Screening Questions (ASQ) — a National Institute of Mental Health-developed and validated 4-item yes/no tool covering a current wish to be dead, current thoughts of suicide, any past suicide attempt, and any current specific plan; it takes under 20 seconds to administer and is validated across both youth and adult populations in medical settings. A "yes" response to any item is a positive screen warranting further assessment.[10]
PHQ-9 item 9 — for a patient already completing a PHQ-9 for depression, item 9 specifically screens for thoughts of death or self-harm and must never be skipped or treated as optional, even when the total score is otherwise reassuring. A positive response on item 9 independently identifies a meaningfully elevated risk of a future suicide attempt or death — one that emerges over the following days and continues to grow over the following months, making it a marker of an enduring vulnerability rather than only an acute, point-in-time concern to note and move past.[11]
Columbia-Suicide Severity Rating Scale (C-SSRS) — a more detailed, validated structured interview that distinguishes ideation severity (from a passive wish to be dead through active ideation with a plan and intent) from actual suicidal behaviour, and is widely used by mental health and emergency services for fuller risk stratification once a brief screen is positive.[7] A community pharmacist does not need to administer the full C-SSRS, but understanding its severity framework meaningfully improves the accuracy of a hand-off — "positive screen, active ideation, no reported plan or intent" and "active ideation with a specific plan" describe two very different situations and should never be collapsed into the same vague hand-off statement.
What a positive screen means — and does not mean
A positive screen on any of these tools identifies a patient who needs a further, more detailed conversation about safety — it is not itself an emergency by definition, and most positive screens do not represent imminent danger. The purpose of a brief structured follow-up conversation is specifically to place the patient correctly on the spectrum described in Recognize the Condition, since that placement is exactly what determines whether the encounter proceeds to Red Flags & Refer's emergency pathway or to the non-emergency warm hand-off and safety-planning pathway in Choose Initial Treatment.
Treatment Targets
- Keep the patient physically safe through the acute crisis window — the first and non-negotiable priority.
- Reduce access to a lethal means during any period of heightened risk — the single pharmacist-specific target with the most direct population-level evidence behind it (see Choose Initial Treatment and Drug Tables).
- Connect the patient to appropriate mental health care through a genuine warm hand-off, not simply a phone number handed over passively.
- Build and reinforce concrete protective factors — social connectedness, a written safety plan, and a specific reason to stay engaged with care.
- Treat the underlying condition driving risk — depression, psychosis, substance use disorder, or an acute situational crisis — coordinating with the relevant condition-specific chapter and care team rather than treating "suicide risk" as a stand-alone diagnosis.
- Maintain continuity of care through the highest-risk window following a crisis, hospitalization, or emergency department visit (see Special Populations and Monitoring & Follow-Up).
- Reduce stigma in every interaction — language and tone are not incidental to this work (see Common Errors to Avoid).
- Involve family members and caregivers appropriately, and with the patient's consent, wherever doing so genuinely strengthens safety.
Choose Initial Treatment
The very first task after any positive screen or warning sign is establishing where the patient sits on the spectrum described in Recognize the Condition. Any reported plan, expressed intent, or access to a means moves the encounter directly to Red Flags & Refer's emergency pathway — stop there and escalate rather than continuing through the steps below.
Ask structured follow-up questions to understand the fuller picture — frequency and duration of the thoughts, any specific (even if not imminent) plan, any prior attempt — then build a brief, collaborative, written safety plan with the patient before they leave (see Non-Pharmacologic Treatment). Arrange a genuine hand-off to an existing or new mental health or primary care contact, or offer 9-8-8 as an immediate bridge while that connection is being arranged. Sending a patient away with only a phone number as the sole next step is not an adequate response to a positive screen.
Genuine centerpiece of this chapter for every patient with an identified acute risk factor, and as routine good practice for any patient newly started on, or regularly using, a recognized high-toxicity-in-overdose medication class (opioids, benzodiazepines, tricyclic antidepressants, or lithium — see Drug Tables), have a brief, collaborative conversation about secure storage, sensible dispensing quantity, and take-back of unused medication.[12] Frame this exactly the way any other medication-safety stewardship conversation is framed — the same way a pharmacist already counsels on keeping opioids away from children, for example — not as an accusation, and not reserved only for a patient who has explicitly disclosed suicidal thoughts.
Health Canada's advisory on newer antidepressants specifically flags the first weeks of treatment and any dose change as a period requiring closer monitoring for worsening mood or emerging suicidal thoughts, across all ages.[13] A reasonable, practical pharmacist practice is a brief check-in call or a specifically scheduled early follow-up within the first 1-2 weeks of a new antidepressant or a dose increase — not simply waiting for the next routine refill to notice a problem.
Do not promise unconditional confidentiality ("I won't tell anyone") before hearing what a patient discloses — be honest that a genuine safety concern needs to be shared with appropriate people.
Do not attempt to argue or debate a person out of suicidal thoughts, or minimize their distress by comparison to others.
Do not leave a person alone who has disclosed an imminent plan or intent, even briefly, while arranging help.
Do not default to dispensing a full, extended quantity of a high-toxicity-in-overdose medication to a patient with a newly identified acute risk factor without a brief conversation with the prescriber first.
Non-Pharmacologic Treatment
Collaborative safety planning
The Stanley-Brown Safety Planning Intervention is the most widely used, evidence-based brief intervention for this purpose: a short, structured plan built with the patient, not handed to them, covering personal warning signs, internal coping strategies the patient can use alone, people and social settings that provide distraction, people to reach out to for direct help, professional and crisis resources (including 9-8-8), and a means-restriction plan specific to that patient's own situation.[14] A pharmacist does not need specialized mental health training to help build or reinforce one — the structure itself is straightforward, and any member of the care team with an existing relationship with the patient can meaningfully contribute to it.
Structured psychotherapy for the underlying condition
Cognitive behavioural therapy specifically adapted for suicide prevention, and dialectical behavior therapy where a personality disorder or a chronic pattern of self-harm is present (see the Borderline Personality Disorder chapter), both have genuine evidence for reducing repeat suicidal behaviour and should form the treatment backbone for a patient with ongoing risk — not medication alone (see Pharmacologic Treatment Options).
Caring contacts — a genuinely evidence-based, low-intensity follow-up practice
Brief, low-cost, non-demanding contact after a crisis — a caring phone call, message, or card checking in with no clinical agenda attached — has shown a real reduction in subsequent suicidal behaviour in randomized trials, and remains one of the only interventions ever shown to reduce death by suicide itself in a controlled trial.[15] A pharmacist's own routine refill check-in, when a patient is known to be at elevated risk, is a genuinely meaningful opportunity to apply this same principle — a brief, sincere "how have you been doing since we last spoke" at pickup is not a small thing.
Family and caregiver involvement
With the patient's consent, involve a trusted family member or caregiver directly in both safety planning and means-restriction measures — holding or securing medication temporarily, being aware of the safety plan, and knowing when and how to seek emergency help. This is especially valuable for a patient living with others who can meaningfully reduce access to a means during a high-risk period (see Drug Tables).
Language and stigma
Use "died by suicide" rather than "committed suicide" — the latter carries a criminal or moral connotation dating to when suicide was itself a criminal offence, and current Canadian safe-messaging guidance specifically recommends against it.[16] Avoid describing an attempt as "successful" or "unsuccessful," and avoid sensationalized, graphic, or judgmental language in any conversation or documentation, including in communication with colleagues.
Special Populations
Adolescents and youth
The ASQ is validated in this age group and takes under 20 seconds to use.[10] Involve a parent or guardian directly in medication storage decisions, especially when a new antidepressant is being started, given Health Canada's specific advisory about closer monitoring in the early weeks of treatment across all ages.[13] School pressures, cyberbullying, and social-media-related distress are common, real contributors to risk in this population and are worth asking about directly rather than assuming an adult-framed conversation will surface them.
Indigenous peoples
Some First Nations, Inuit, and Métis communities in Canada experience suicide rates substantially above the national average, reflecting the ongoing impact of colonization, intergenerational trauma, and inequitable access to culturally safe care — a pattern current national suicide-prevention planning explicitly names as a priority.[6] The Hope for Wellness Help Line (1-855-242-3310, available 24 hours a day by phone and online chat) is a specific, culturally grounded crisis resource for Indigenous people across Canada, offered in English and French with Cree, Ojibway, and Inuktitut support available — a distinct, complementary resource to keep on hand alongside 9-8-8 rather than assuming one crisis line fits every community equally well.[20]
2SLGBTQ+ individuals
Elevated risk in this population is tied to stigma, discrimination, and family or social rejection, and is particularly pronounced among 2SLGBTQ+ youth. Affirming, nonjudgmental care — including using a patient's correct name and pronouns in every interaction — is itself a protective, safety-relevant practice in this context, not simply a courtesy.
Older adults
Risk in older adults, especially older men, is genuinely under-recognized because the presentation is often quieter than the stereotype of overt distress — withdrawal, giving away possessions, or "putting affairs in order" rather than dramatic warning signs. Chronic pain and serious or terminal illness are real, independent risk factors in this group, and polypharmacy together with any cognitive concerns can complicate both risk assessment and means-restriction counselling — involve a caregiver directly wherever one is available and the patient consents.
The postpartum period
Postpartum psychosis is a distinct, rare, and genuine psychiatric emergency carrying an elevated risk of both suicide and, rarely, infanticide — see the Postpartum Depression chapter's Red Flags & Refer section for the full picture. Any postpartum patient expressing suicidal ideation warrants the same emergency escalation described in this chapter's own Red Flags & Refer section.
Recent psychiatric hospitalization or an emergency department visit for self-harm
The period immediately following discharge carries the highest suicide risk of any point across the entire course of care. A pooled meta-analysis found the postdischarge suicide rate was highest in the first 3 months after discharge, at roughly 100 times the global average rate, and nearly 200 times the global average specifically among patients admitted for suicidal thoughts or behaviour.[9] A pharmacist filling a first post-discharge prescription, or noticing that a newly prescribed medication has not yet been picked up, is in a genuinely important position during this specific window (see Monitoring & Follow-Up).
Chronic pain and serious or terminal illness
Both are independent, meaningful risk factors, and means-restriction counselling is particularly relevant given how often these patients are concurrently prescribed opioids or another high-toxicity-in-overdose medication class (see Drug Tables). Balance this directly against not under-treating legitimate pain — the goal is safe stewardship and open conversation, never withholding needed treatment.
Rural and remote communities
Reduced access to in-person crisis and mental health services makes 9-8-8's phone-and-text access, and virtual or telehealth mental health options, particularly important bridges to care. In some communities, the pharmacist is genuinely the most consistently accessible regulated health professional a patient will see.
Monitoring & Follow-Up
- Reassess directly at every relevant encounter for a patient with a known elevated-risk history, not only at the point of an initial disclosure — risk changes over time, and a stable period does not mean the conversation is finished.
- Apply the caring-contacts principle deliberately for a patient known to be at elevated risk: a brief, genuine check-in at pickup, or a scheduled call, particularly during the days-to-weeks following any crisis, hospitalization, or emergency department visit.[15]
- Watch specifically for a gap in filling a first post-discharge prescription, or a missed pickup, in a patient known to be in this elevated-risk window — treat it as a signal worth a proactive call rather than a routine administrative gap (see Special Populations).[9]
- For any patient newly started on, or with a recently changed dose of, an antidepressant, schedule closer early monitoring in the first 1-2 weeks rather than waiting for the next routine refill.[13]
- Revisit the means-restriction conversation at every relevant refill or encounter, not as a single one-time event — a patient's clinical situation, living arrangement, and risk level can all change between visits (see Drug Tables).
- Review and update the collaborative safety plan regularly together with the patient, treating it as a living document rather than paperwork completed once and filed away.
- For a patient on clozapine specifically, track adherence to the mandatory neutrophil monitoring program as a genuine continuity-of-treatment issue, not only a hematologic-safety one (see Pharmacologic Treatment Options).
Common Errors to Avoid
- Believing that asking directly about suicide will "plant the idea" or increase risk — the evidence points the opposite way, and avoiding the question out of this fear is a genuinely common, avoidable error.[2]
- Using indirect or euphemistic language ("you're not thinking of doing something silly, are you?") instead of a direct, plain-language question.
- Dismissing a repeated disclosure as attention-seeking rather than treating every disclosure as a genuine clinical symptom.
- Promising unconditional confidentiality before hearing what a patient discloses, then having to walk that promise back at the worst possible moment.
- Treating means-restriction counselling as a one-time checkbox rather than an ongoing conversation revisited as a patient's risk and circumstances change.
- Defaulting to dispensing a full, extended quantity of a high-toxicity-in-overdose medication to a patient with a newly identified acute risk factor without a brief conversation with the prescriber first.
- Sending a patient away after a positive screen with only a crisis-line phone number as the sole next step, rather than a genuine warm hand-off.
- Overlooking the sharply elevated risk in the days-to-weeks immediately following psychiatric hospital discharge or an emergency department visit for self-harm, and treating a missed pickup during that window as routine.[9]
- Using stigmatizing language such as "committed suicide" (rather than "died by suicide") or describing an attempt as "successful," in conversation or in documentation.[16]
- Assuming a patient does not fit the risk profile because of their age, gender, or outward presentation — older men and other under-recognized groups are genuinely, not just theoretically, at risk (see Risk Factors and Special Populations).
- Leaving a person alone, even briefly, after they have disclosed an imminent plan or intent.
- Failing to involve a willing, consenting family member or caregiver in safety planning and means restriction when one is available.
Clinical Decision Algorithm
Drug Tables
How to use this table: this table exists to guide means-restriction counselling and dispensing stewardship — it is not a treatment or dosing reference. See Choose Initial Treatment and Non-Pharmacologic Treatment for the full counselling approach. Select any drug name to open its complete Pharmasist Drug Database page.
| Medication class | Why it is a means-restriction priority | Stewardship / dispensing practice | Patient & caregiver counselling points |
|---|---|---|---|
| Opioids (e.g., morphine, hydromorphone, oxycodone) | A recognized, common contributor to overdose deaths, whether intentional or unintentional; risk compounds meaningfully with any concurrent CNS depressant or alcohol use. | For a patient with an identified acute risk factor, discuss a clinically appropriate quantity and refill interval with the prescriber rather than dispensing a full, extended supply by default; a brief, collaborative shift to more frequent, shorter-interval dispensing is a reasonable, time-limited measure. | Offer naloxone and counsel on its use for any patient on a regular opioid regimen, regardless of the specific reason for concern; counsel on secure storage separate from other household medications, and encourage prompt take-back of any discontinued or leftover supply. |
| Benzodiazepines (e.g., diazepam, lorazepam, clonazepam) | Commonly co-prescribed with other CNS depressants, with additive risk in combination; an accumulated as-needed supply sitting unused at home is itself a modifiable factor. | Reassess whether ongoing dispensing at full quantity remains appropriate for a patient with escalating risk; a brief, collaborative conversation with the prescriber about interval dispensing is reasonable rather than an abrupt, unilateral pharmacist decision. | Encourage secure storage, discourage stockpiling of an as-needed supply beyond current genuine need, and support take-back of any unused portion after a dose or regimen change. |
| Tricyclic antidepressants (e.g., amitriptyline, nortriptyline) | Recognized toxicity in overdose distinct from that of newer antidepressants; a smaller quantity in the home represents a meaningful safety margin. | For a patient with an identified acute risk factor being newly started on a TCA — commonly for a non-psychiatric indication such as neuropathic pain — discuss starting with the smallest reasonable trial quantity with the prescriber before committing to a full month's supply. | Explain the rationale for a smaller starting quantity honestly and collaboratively, framed as standard, sensible practice for this drug class rather than as singling the patient out. |
| Lithium | A genuinely narrow therapeutic index — toxicity can occur only modestly above the therapeutic range — and the same property that requires close lab monitoring also makes a large accumulated supply a modifiable risk. | Align dispensing quantity with the monitoring schedule already in place for therapeutic drug levels, rather than dispensing a maximal supply between level checks. | Reinforce adherence to level monitoring as a safety measure in its own right, and involve a family member in secure storage where the patient consents and a caregiver is available (see Special Populations). |
| High-quantity OTC analgesics (e.g., acetaminophen, acetylsalicylic acid) | A large single package of a common household analgesic is itself a modifiable point of access. United Kingdom legislation restricting paracetamol pack sizes was followed by a sustained, substantial reduction in poisoning deaths and liver transplants over the following decade, with no compensatory rise in other methods.[21] | Where local policy or professional judgment supports it, default to a smaller pack size at the point of sale for a patient with an identified risk factor, and avoid selling multiple packages in the same transaction without a specific, legitimate reason. | This is a genuinely evidence-based, low-friction intervention — a brief, natural conversation at checkout, not an accusation. |
| Any medication in an unusually large accumulated quantity | The general principle behind every row above: an unusually large accumulated supply of any medication — not only the specific classes listed here — is itself a modifiable point of access for a patient with an identified acute risk factor. | Apply the same collaborative, prescriber-inclusive reasoning to any medication class where a patient's specific clinical situation raises concern; this table is illustrative of the highest-yield classes, not an exhaustive or rigid list. | Every means-restriction conversation should be framed as temporary, collaborative, and rooted in care — never as a unilateral or permanent restriction — and revisited as the patient's risk and clinical picture change (see Monitoring & Follow-Up). |
References
- Suicide and Self-Harm in Canada: Suicide Mortality — Public Health Agency of Canada, Health Infobase. PHAC Health Infobase, data through 2024 (preliminary), accessed 2026
- Does Asking about Suicide and Related Behaviours Induce Suicidal Ideation? What Is the Evidence? — Psychological Medicine (Dazzi T, Gribble R, Wessely S, Fear NT). Psychol Med 2014;44(16):3361-3363
- Means Restriction for Suicide Prevention — The Lancet (Yip PSF, Caine E, Yousuf S, Chang SS, Wu KC, Chen YY). Lancet 2012;379(9834):2393-2399
- Reducing a Suicidal Person's Access to Lethal Means of Suicide: A Research Agenda — American Journal of Preventive Medicine (Barber CW, Miller MJ). Am J Prev Med 2014;47(3 Suppl 2):S264-S272
- 9-8-8: Suicide Crisis Helpline — Centre for Addiction and Mental Health (CAMH). CAMH, launched 30 November 2023
- The National Suicide Prevention Action Plan (2024 to 2027) — Government of Canada, Public Health Agency of Canada. Public Health Agency of Canada, 2024
- The Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings from Three Multisite Studies with Adolescents and Adults — American Journal of Psychiatry (Posner K, Brown GK, Stanley B, et al.). Am J Psychiatry 2011;168(12):1266-1277
- Suicide — The Lancet (Hawton K, van Heeringen K). Lancet 2009;373(9672):1372-1381
- Suicide Rates After Discharge from Psychiatric Facilities: A Systematic Review and Meta-Analysis — JAMA Psychiatry (Chung DT, Ryan CJ, Hadzi-Pavlovic D, Singh SP, Stanton C, Large MM). JAMA Psychiatry 2017;74(7):694-702
- Ask Suicide-Screening Questions (ASQ) Toolkit — National Institute of Mental Health (NIMH). NIMH ASQ Toolkit
- Does Response on the PHQ-9 Depression Questionnaire Predict Subsequent Suicide Attempt or Suicide Death? — Psychiatric Services (Simon GE, Rutter CM, Peterson D, et al.). Psychiatr Serv 2013;64(12):1195-1202
- Infosheet: Means Restriction in Suicide Prevention (Research and Knowledge Translation Initiative for Suicide Prevention) — Public Health Agency of Canada. Cat. No. HP35-192-2-2025E-PDF, Public Health Agency of Canada, 2025
- Health Canada Advises Canadians of Stronger Warnings for SSRIs and Other Newer Anti-Depressants — Health Canada. Health Canada advisory, 3 June 2004
- Safety Planning Intervention: A Brief Intervention to Mitigate Suicide Risk — Cognitive and Behavioral Practice (Stanley B, Brown GK). Cogn Behav Pract 2012;19(2):256-264
- A Randomized Controlled Trial of Postcrisis Suicide Prevention — Psychiatric Services (Motto JA, Bostrom AG). Psychiatr Serv 2001;52(6):828-833
- Language Matters: Safe Communication for Suicide Prevention — Government of Canada, Public Health Agency of Canada. Public Health Agency of Canada
- Lithium in the Prevention of Suicide in Mood Disorders: Updated Systematic Review and Meta-Analysis — BMJ (Cipriani A, Hawton K, Stockton S, Geddes JR). BMJ 2013;346:f3646
- Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT) — Archives of General Psychiatry (Meltzer HY, Alphs L, Green AI, et al.). Arch Gen Psychiatry 2003;60(1):82-91
- Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation with Intent: Double-Blind, Randomized Study (ASPIRE I) — Journal of Clinical Psychiatry (Fu DJ, Ionescu DF, Li X, et al.). J Clin Psychiatry 2020;81(3):19m13191
- Hope for Wellness Helpline — Indigenous Services Canada. Government of Canada, Indigenous Services Canada
- Long Term Effect of Reduced Pack Sizes of Paracetamol on Poisoning Deaths and Liver Transplant Activity in England and Wales: Interrupted Time Series Analyses — BMJ (Hawton K, Bergen H, Simkin S, et al.). BMJ 2013;346:f403
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.